Education
About Us
Working with TipRanks
Follow Us
Silence Therapeutics (DE:XRP2)
FRANKFURT:XRP2
XRP2 Stock Chart & Stats
€4.00
-€0.85(-11.89%)
At close: 4:00 PM EST
€4.00
-€0.85(-11.89%)
Day’s Range― - ―
52-Week Range€1.70 - €6.55
Previous CloseN/A
Volume0.00
Average Volume (3M)78.00
Market Cap
€195.24M
Enterprise Value€154.32M
Total Cash (Recent Filing)€102.19M
Total Debt (Recent Filing)€182.00K
Price to Earnings (P/E)―
Beta1.33
Next Earnings
Mar 18, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding47,233,948
10 Day Avg. Volume87
30 Day Avg. Volume78
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)0.79
Price to Sales (P/S)2.45
P/FCF Ratio-1.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€63.42Price Target Upside1485.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthVery low leverage and a negligible debt-to-equity profile materially reduce refinancing and interest-rate exposure for a cash-burning biotech. This structural flexibility supports continued R&D and partnership deals, giving management time to progress trials without urgent debt pressures.
Revenue Quality & Gross MarginsMulti-year revenue growth and high gross margins imply attractive underlying product/partner economics when milestones convert. Durable gross economics increase potential operating leverage as revenue stabilizes, making future profitability more achievable if expense growth is controlled.
Pipeline De-risking (Phase 2)Completing Phase 2 enrollment is a structural milestone that reduces clinical development risk and sets a clear medium-term catalyst (trial readout). Successful results would materially change commercialization prospects and partnership leverage; the milestone itself improves program credibility.
Bears Say
Worsening Cash BurnConsistent negative operating and free cash flow that worsened year-over-year signals growing cash burn and dependence on external funding or partnership receipts. Over a 2–6 month horizon this elevates funding risk and could force dilutive financings or reduced program spend if inflows don't arrive.
Deepening LossesWidening operating and net losses reflect that development and SG&A expense intensity still overwhelm revenue. Persistently negative profitability erodes equity cushions and reduces optionality for strategic investments, making sustainable long-term progress contingent on funding or dramatic revenue inflection.
Leadership Transition RiskAn unexpected CEO departure and interim leadership create governance and execution uncertainty during a critical clinical window. Short-term disruptions can slow fundraising, partner negotiations, and trial execution, raising operational risk over the next several months until permanent leadership is in place.
Silence Therapeutics News
XRP2 FAQ
What was Silence Therapeutics’s price range in the past 12 months?
Silence Therapeutics lowest stock price was €1.70 and its highest was €6.55 in the past 12 months.
What is Silence Therapeutics’s market cap?
Silence Therapeutics’s market cap is €195.24M.
When is Silence Therapeutics’s upcoming earnings report date?
Silence Therapeutics’s upcoming earnings report date is Mar 18, 2026 which is in 23 days.
How were Silence Therapeutics’s earnings last quarter?
Silence Therapeutics released its earnings results on Nov 06, 2025. The company reported -€0.127 earnings per share for the quarter, beating the consensus estimate of -€0.158 by €0.031.
Is Silence Therapeutics overvalued?
According to Wall Street analysts Silence Therapeutics’s price is currently Undervalued.
Does Silence Therapeutics pay dividends?
Silence Therapeutics does not currently pay dividends.
What is Silence Therapeutics’s EPS estimate?
Silence Therapeutics’s EPS estimate is -0.16.
How many shares outstanding does Silence Therapeutics have?
Silence Therapeutics has 47,233,948 shares outstanding.
What happened to Silence Therapeutics’s price movement after its last earnings report?
Silence Therapeutics reported an EPS of -€0.127 in its last earnings report, beating expectations of -€0.158. Following the earnings report the stock price went down -4.63%.
Which hedge fund is a major shareholder of Silence Therapeutics?
Currently, no hedge funds are holding shares in DE:XRP2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Silence Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-10.12%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-35.39%
Trailing 12-Months
Company Description
Silence Therapeutics
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatment of cardiovascular disease with high lipoprotein; SLN124 that is in Phase I clinical trials for the treatment of non-transfusion dependent thalassemia, and Phase I clinical trials for the treatment of myelodysplastic syndrome; and SLN124 for the treatment of polycythemia vera. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize small interfering RNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company also has a collaboration with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three undisclosed targets leveraging Silence's mRNAi GOLD platform. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc is headquartered in London, the United Kingdom.
XRP2 Stock 12 Month Forecast
Average Price Target
€63.42
▲(1485.44% Upside)
Technical Analysis
Options Prices
Currently, No data available
---